References
- Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 2021; 157: 308–47. doi: 10.1016/j.ejca.2021.07.039
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49. doi: 10.3322/caac.21660
- Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212–21. doi: 10.1016/j.ejca.2006.04.012
- Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 2014; 14: 810. doi: 10.1186/1471-2407-14-810
- Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer 2018; 18: 78. doi: 10.1186/s12885-017-3925-x
- Brecelj E, Velenik V, Reberšek M, Boc N, Oblak I, Zadnik V, et al. [Recommendations for the diagnosis and treatment of patients with colorectal cancer]. [Slovenian]. Onkologija 2020; 6: 60–92. doi: 10.25670/oi2020-012on
- Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 016; 27: 1386–422. doi: 10.1093/annonc/mdw235
- Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 10–32. doi: 10.1016/j.annonc.2022.10.003
- Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepatic Oncol 2020; 21;7: HEP16. doi: 10.2217/hep-2019-0010
- Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolisation. Med Oncol 2017; 34: 37. doi: 10.1007/s12032-017-0890-9
- Szemitko M, Golubinska-Szemitko E, Sienko J, Falkowski A, Wiernicki I. Efficacy of liver chemoembolization after prior cetuximab monotherapy in patients with metastatic colorectal cancer. Cancers 2023; 15: 541. doi: 10.3390/cancers15020541
- Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, et al. Irinotecan-eluting 75–150-mum embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center Phase I study. J Vasc Interv Radiol 2018; 29: 1646–53. doi: 10.1016/j.jvir.2018.08.010
- Iezzi R, Marsico VA, Guerra A, Cerchiaro E, Cassano A, Basso M, et al. Transarterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a Phase II single-center study. Cardiovasc Intervent Radiol 2015; 6:1523–31. doi: 10.1007/s00270-015-1080-9
- Martin RCG, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121: 3649–58. doi: 10.1002/cncr.29534
- Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the Cirse classification system. Cardiovasc Intervent Radiol 2017; 40: 1141–6. doi: 10.1007/s00270-017-1703-4
- Ocvirk J, Moltara ME, Mesti T, Boc M, Rebersek M, Volk N, et al. Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience. Radiol Oncol 2016; 50: 226–31. doi: 10.1515/raon-2015-0030
- Saletti P, Molinari F, De Dosso S, Frattini M. EGFR signaling in colorectal cancer: a clinical perspective. Gastrointest Cancer Targets Ther 2015; 5: 21–38. doi: 10.2147/GICTT.S49002
- Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol 2020; 11: 761–808. doi: 10.5306/wjco.v11.i10.761
- Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D’Argento E, et al. DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. Future Oncol Lond Engl 2019; 15: 2349–60. doi: 10.2217/fon-2017-0025
- Voizard N, Ni T, Kiss A, Pugash R, Raphael MJ, Coburn N, et al. Small particle DEBIRI TACE as salvage therapy in patients with liver dominant colorectal cancer metastasis: retrospective analysis of safety and outcomes. Curr Oncol Tor Ont 2022; 29: 209–20. doi: 10.3390/curroncol29010020
- Pereira PL, Iezzi R, Manfredi R, Carchesio F, Bánsághi Z, Brountzos E, et al. The CIREL cohort: a prospective controlled registry studying the real-life use of irinotecan-loaded chemoembolisation in colorectal cancer liver metastases: interim analysis. Cardiovasc Intervent Radiol 2021; 44: 50–62. doi: 10.1007/s00270-020-02646-8